Neha Net In

Complete timeline clarity about bidding period and expected listing milestone for new IPO launch

The Gaudium IVF IPO date has become one of the most discussed launch timelines in recent Indian primary market activity, with investors tracking every milestone from subscription start to the anticipated listing day on major exchanges. The Initial Public Offering by Gaudium IVF & Women Health Ltd, a provider of fertility and reproductive healthcare services, opened for public subscription starting 20?February?2026 and closed for bids on 24?February?2026 as part of a ?165?crore book building issue estimated at the price band of ?75 to ?79 per share.

The announcement of the Gaudium IVF IPO date was met with notable attention because this IPO represents a relatively niche healthcare segment entering the public markets, targeting individual investors and institutional participants alike. The company’s offering included both fresh equity shares and an offer for sale by the promoter, Dr. Manika Khanna, with a substantial component of capital intended to finance expansion plans such as adding new IVF centres across several regions. This pricing and timing structure meant that market participants watched bids closely from the opening date through to the closing date, which affects not only subscription figures but also the sentiment measured unofficially in grey market trends throughout the issue period.

The Gaudium IVF IPO date was significant because the subscription window provided a limited but well?defined timeframe for bids. Starting on 20?February?2026, the public issue allowed investors to participate in the equity offering with a minimum lot size communicated in advance. The bidding period spanned just a few days, closing on 24?February?2026, and by then the IPO had attracted healthy participation across categories with oversubscription reported in retail and non?institutional investor segments. The closing of bids marked a key benchmark in the IPO’s timeline and set the stage for subsequent public listing procedures.

Following the end of the bidding period on 24?February?2026, the next critical milestone in the Gaudium IVF IPO date sequence was the basis of allotment, which was scheduled for 25?February?2026 when the registrar would finalise and announce the allocation of shares to successful applicants. After allotment confirmation, refunds for non?allotted bids and credit of shares to investor demat accounts usually take place quickly. For this IPO, credits to demat accounts were expected to occur on 26?February?2026, allowing investors to see their allocations appear before the anticipated listing.

One of the most anticipated outcomes tied to the Gaudium IVF IPO date was the public listing event, when the company’s shares would start trading on major exchanges such as the BSE and NSE. According to confirmed timelines from multiple market sources, the listing was scheduled for 27?February?2026, shortly after the allotment and settlement processes are completed. This listing date is a key moment because it brings together all pre?issue activity into the live trading phase, enabling buyers and sellers to establish a market price based on public demand and supply dynamics.

Understanding the Gaudium IVF IPO date and its surrounding timeline highlights the structured nature of IPO launches in India under the regulatory framework. The sequence starts with the issue open date, continues through the subscription closing date, and progresses into allotment and listing dates. Each step is a distinct event in the lifecycle of an IPO, and tracking this timeline helps investors and learners of primary markets know when to prepare for bidding, when to check allocation status, and when to anticipate first trading on exchanges.

It is important for individuals monitoring primary market activity to realise that the Gaudium IVF IPO date not only signals the start of public subscription but also determines the pacing of all subsequent processes. The opening date on 20?February?2026 allowed retail and institutional participants to bid within a clearly defined window that concluded on 24?February?2026. This concise bidding period is common for many issues, and the specific dates provide a reference for planning investment participation or analysis of subscription trends.

As the issue closed on the final subscription day, the next significant date was the allotment date (25?February?2026) and the expected listing date (27?February?2026). These dates are part of the sequence that market watchers and analysts follow to understand how demand during the subscription period might translate into listing performance on stock exchanges. For example, strong oversubscription in retail categories can hint at positive sentiment that may influence trading pressures on the first listed day.

At ICFM – Stock Market Institute, learners are encouraged to pay attention to how a timeline like the Gaudium IVF IPO date impacts analysis and decision frameworks when studying primary market participation. Understanding the intervals between subscription open and close, allotment announcements, and listing events helps market learners grasp the full lifecycle of an IPO. This knowledge builds analytical skills that are useful not just around one specific company’s public issue but also in evaluating future IPOs and mapping anticipated investor behaviour. Integrating timeline awareness with broader company fundamentals and subscription dynamics allows learners to form more complete perspectives that go beyond basic date tracking.

In conclusion, the Gaudium IVF IPO date remains a core reference point that anchors all related activity from subscription beginnings on 20?February?2026 to the expected listing on 27?February?2026. These dates provide a clear sequence that demarcates when the issue opened, closed, and progressed toward public trading, allowing participants to plan and review their engagement with the public issue effectively. By understanding this timeline and connecting it with subscription trends and company fundamentals, learners and investors can develop informed perspectives on IPO processes and market participation.